Sign In
Buy TARS
Tarsus Pharmaceuticals Earnings Calls
| Release date | May 06, 2026 |
| EPS estimate | -$0.402 |
| EPS actual | -$0.160 |
| EPS Surprise | 60.17% |
| Revenue estimate | 149.599M |
| Revenue actual | 162.054M |
| Revenue Surprise | 8.33% |
| Release date | Feb 23, 2026 |
| EPS estimate | -$0.103 |
| EPS actual | -$0.200 |
| EPS Surprise | -94.17% |
| Revenue estimate | 144.565M |
| Revenue actual | 151.668M |
| Revenue Surprise | 4.91% |
| Release date | Nov 04, 2025 |
| EPS estimate | -$0.350 |
| EPS actual | -$0.300 |
| EPS Surprise | 14.29% |
| Revenue estimate | 144.638M |
| Revenue actual | 118.697M |
| Revenue Surprise | -17.93% |
| Release date | Aug 06, 2025 |
| EPS estimate | -$0.330 |
| EPS actual | -$0.480 |
| EPS Surprise | -45.45% |
| Revenue estimate | 113.047M |
| Revenue actual | 102.66M |
| Revenue Surprise | -9.19% |
Last 4 Quarters for Tarsus Pharmaceuticals
Below you can see how TARS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $41.64 |
| EPS estimate | -$0.330 |
| EPS actual | -$0.480 |
| EPS surprise | -45.45% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $38.82 |
| Aug 01, 2025 | $40.81 |
| Aug 04, 2025 | $41.91 |
| Aug 05, 2025 | $41.15 |
| Aug 06, 2025 | $41.64 |
| Aug 07, 2025 | $47.95 |
| Aug 08, 2025 | $47.85 |
| Aug 11, 2025 | $50.07 |
| Aug 12, 2025 | $51.36 |
| 4 days before | 7.26% |
| 4 days after | 23.34% |
| On release day | 15.15% |
| Change in period | 32.30% |
| Release date | Nov 04, 2025 |
| Price on release | $71.50 |
| EPS estimate | -$0.350 |
| EPS actual | -$0.300 |
| EPS surprise | 14.29% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $67.52 |
| Oct 30, 2025 | $68.96 |
| Oct 31, 2025 | $68.81 |
| Nov 03, 2025 | $69.79 |
| Nov 04, 2025 | $71.50 |
| Nov 05, 2025 | $68.20 |
| Nov 06, 2025 | $68.09 |
| Nov 07, 2025 | $68.25 |
| Nov 10, 2025 | $72.79 |
| 4 days before | 5.89% |
| 4 days after | 1.80% |
| On release day | -4.62% |
| Change in period | 7.81% |
| Release date | Feb 23, 2026 |
| Price on release | $69.59 |
| EPS estimate | -$0.103 |
| EPS actual | -$0.200 |
| EPS surprise | -94.17% |
| Date | Price |
|---|---|
| Feb 17, 2026 | $62.78 |
| Feb 18, 2026 | $63.27 |
| Feb 19, 2026 | $65.54 |
| Feb 20, 2026 | $66.61 |
| Feb 23, 2026 | $69.59 |
| Feb 24, 2026 | $75.01 |
| Feb 25, 2026 | $72.65 |
| Feb 26, 2026 | $75.87 |
| Feb 27, 2026 | $75.52 |
| 4 days before | 10.85% |
| 4 days after | 8.52% |
| On release day | 7.79% |
| Change in period | 20.29% |
| Release date | May 06, 2026 |
| Price on release | $64.76 |
| EPS estimate | -$0.402 |
| EPS actual | -$0.160 |
| EPS surprise | 60.17% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $63.61 |
| May 01, 2026 | $63.62 |
| May 04, 2026 | $64.57 |
| May 05, 2026 | $65.04 |
| May 06, 2026 | $64.76 |
| May 07, 2026 | $63.96 |
| May 08, 2026 | $61.21 |
| May 11, 2026 | $59.65 |
| May 12, 2026 | $59.83 |
| 4 days before | 1.81% |
| 4 days after | -7.61% |
| On release day | -1.24% |
| Change in period | -5.94% |
Tarsus Pharmaceuticals Earnings Call Transcript Summary of Q1 2026
Tarsus reported a strong start to 2026 driven by XDEMVY momentum: Q1 net product sales were $145.4M, up >85% year-over-year, with improving physician adoption, depth of prescribing, retreatment rates (mid-teens trending toward a steady-state ~20%), and a high-performing DTC campaign (Find-a-Doctor engagement up ~40% QoQ). Management is deploying a targeted Key Account Leader (KAL) team in H2 2026 to expand utilization in high-opportunity practices. Financials and guidance: reiterated full-year 2026 guidance of $670M–$700M net product sales, SG&A $545M–$565M, R&D $115M–$135M, and ~93% gross margin; license/collaboration revenue included a one-time $15M milestone from Grand Pharma following TP-03 approval in Greater China. Pipeline progress: initiated Calliope (≈700‑patient Phase II of TP-05 for on‑demand Lyme disease prophylaxis) with topline data expected in H1 2027 and the TP-04 ocular rosacea Phase II (KORE) also expected to report topline data in H1 2027. Management expects continued seasonality (strong Q2, softer Q3, robust Q4) and remains confident in achieving full‑year guidance while advancing category-creating programs that could meaningfully expand addressable markets for eye care and beyond.
